The Question Nobody Asks Early Enough
When you are developing a nanoparticle drug product, the bioanalytical question you need to answer is not simply ‘how much drug is in the blood?’ It is ‘which form of the drug are you measuring, and what does that tell you about what is actually happening in the patient?’
For a conventional small molecule, total plasma drug concentration is a reliable surrogate for the concentration available to interact with the target. For a nanoparticle product, the drug in the plasma exists in at least two distinct populations: drug encapsulated within intact nanoparticles (not directly bioavailable until the particle releases it), and free drug (the fraction that has been released and is available for cellular uptake or systemic distribution). These two fractions have different pharmacokinetic profiles, different safety implications, and different relationships to efficacy. Measuring only the total gives you a misleading picture of both.
The Three Fractions and What They Tell You
| Analyte Fraction | What It Represents | Clinical Relevance | Measurement Approach |
| Total drug (encapsulated + free) | Everything in the sample, regardless of form | Overall systemic exposure; comparison to free drug PK for benefit of encapsulation | Extract with detergent or organic solvent before analysis; LC-MS/MS or validated immunoassay |
| Free (unencapsulated) drug | Drug released from the particle in circulation | Off-target toxicity risk; available for direct cellular uptake; clearance profile | Separate free fraction by ultrafiltration or SEC before extraction; subtract from total |
| Encapsulated drug | Drug retained within intact nanoparticles | Depot of drug still in delivery system; circulation half-life of the carrier | Calculated as total minus free; or direct measurement after nanoparticle enrichment |
How to Separate the Fractions
Ultrafiltration
Centrifugal ultrafiltration is the most commonly used approach for separating free drug from encapsulated drug. The sample is centrifuged through a membrane with a molecular weight cut-off appropriate to retain the nanoparticles while allowing free drug to pass into the filtrate. The free drug is then quantified in the filtrate, and total drug is measured in a separately extracted aliquot of the unprocessed sample.
The main limitation of ultrafiltration is the potential for non-specific binding of the drug to the membrane, which can lead to underestimation of the free fraction. Membrane compatibility must be assessed during method development using spiked samples at relevant concentrations.
Size Exclusion Chromatography
Size exclusion chromatography (SEC) physically separates nanoparticles from free drug based on size. Nanoparticles elute in the void volume; free drug elutes later. Fractions can be collected and analysed separately. SEC is gentler than ultrafiltration for fragile nanoparticle formulations and avoids membrane binding artefacts, but is lower throughput and requires careful method development to ensure complete separation.
Matrix-Specific Challenges for Nanoparticle PK Assays
Nanoparticle products interact with blood components in ways that complicate sample handling. Plasma proteins adsorb to nanoparticle surfaces to form a protein corona within seconds of contact with blood, changing the particle’s surface properties and, in some assays, interfering with the detection of the encapsulated payload. Lipid nanoparticles can fuse with endogenous lipoproteins in plasma, causing transfer of lipid payload and apparent changes in the free-to-encapsulated ratio that are artefacts of the in vitro processing rather than the in vivo behaviour.
These matrix interactions must be characterised during method development and controlled by standardised sample collection and processing procedures. Samples for nanoparticle PK analysis should be processed promptly after collection, and freeze-thaw stability of the sample before the separation step must be validated to confirm that particle integrity is maintained under study storage conditions.
Regulatory Expectations for Nanoparticle PK Bioanalysis
The FDA and EMA have not yet published dedicated guidance specifically on bioanalytical methods for nanoparticle drug products, but the general principles of ICH M10 apply. Sponsors developing nanoparticle products are expected to define the analyte clearly in the validation protocol, to justify the choice of measurement (total versus free versus encapsulated), and to demonstrate that the sample preparation procedure does not introduce systematic bias through nanoparticle disruption or membrane binding. FDA review comments on approved nanoparticle products provide useful precedent for the level of characterisation expected.
Ardena’s Nanoparticle Payload Bioanalysis at Assen
Ardena’s bioanalytical team in Assen develops and validates methods for nanoparticle payload quantification using ultrafiltration and SEC-based fractionation combined with LC-MS/MS detection. The team has experience with liposomal, LNP, and polymeric nanoparticle products, and can advise on bioanalytical strategy design to ensure the PK data package supports both dose selection decisions and the regulatory filing.
